An Open-label, Pharmacokinetic, Pharmacodynamic, and Tolerability Study of AVE5026 Administered at Weight-adjusted Doses to Patients Less Than 18 Years of Age With a Central Venous Line (CVL) [Estudio abierto, de farmacocinética y farmacodinámica, y tolerabilidad de AVE5026 administrado en dosis ajustadas al peso a pacientes menores de 18 años con una vía venosa central (VVC)]
Phase of Trial: Phase II
Latest Information Update: 05 May 2016
At a glance
- Drugs Semuloparin (Primary)
- Indications Thromboembolism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Sanofi
- 14 Jan 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
- 11 Jul 2012 Planned End Date changed from 1 Sep 2014 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 11 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.